VALIDATED EXECUTIVE ENGAGEMENTS
POOL + OUTREACH
3682
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
662
Interactions with Platform & by Email
PARTICIPANTS
112
Unique # Participated
VALIDATIONS
51
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
JULY 2020
TABLES
159
PAGES
235
EDITION
8
PRICE
USD $4950
Is the U.S. Still a Better Global Barometer than China?
COVID-19 IMPACT SURVEY
GLOBAL EXECUTIVE SURVEY
Impact of Pandemic & Economic Slowdown
Monitor Market Dynamics!
Early March 2020, we reached out to senior enterprise executives who are driving strategy, business development, marketing, sales, product management, technology and operations at competitive firms worldwide. Our ongoing survey is focused on how this will this affect their business ecosystems. We invite you to participate in our survey and add to collective perspectives. Market movements are tracked for 2020, 2021 and broadly for the period of 2022 through 2025. Critical changes are monitored dynamically for the rest of this year. Updated analytics will reflect new and evolving market realities. Our first update scheduled for May 2020 and another in the Fall. Clients receive complimentary updates during 2020. If your company is a recent client for this project, we may have already reached out to your colleagues to participate in our program. If you're an active player in the space but hasn't yet subscribed to our project, we invite you to participate and share your perspectives. Please sign-up here.
Amid the COVID-19 crisis, the global market for Alpha 1 Antitrypsin Deficiency Treatment estimated at US$1.6 Billion in the year 2020, is projected to reach a revised size of US$2.9 Billion by 2027, growing at a CAGR of 8.9% over the analysis period 2020-2027. Augmentation Therapy, one of the segments analyzed in the report, is projected to record a 9.7% CAGR and reach US$1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Bronchodilator segment is readjusted to a revised 9.4% CAGR for the next 7-year period.
The Alpha 1 Antitrypsin Deficiency Treatment market in the U.S. is estimated at US$463.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$493.1 Million by the year 2027 trailing a CAGR of 8.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.
In the global Corticosteroids segment, USA, Canada, Japan, China and Europe will drive the 7.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$189.6 Million in the year 2020 will reach a projected size of US$319.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$328.4 Million by the year 2027.We bring years of research experience to this 8th edition of our report. The 235-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Abeona Therapeutics Inc.; Applied Genetic Technologies Corporation; Arrowhead Pharmaceuticals Inc.; AstraZeneca PLC; Baxter International, Inc.; Biogen, Inc.; Boehringer Ingelheim International GmbH; Chiesi Farmaceutici SpA; CSL Behring; Curaxys; GlaxoSmithKline PLC; Grifols International SA; Kamada Ltd.; Pfizer, Inc.; ProBioGen AG; ProMetic Life Sciences, Inc.; Shire PLC; Teva Pharmaceutical Industries Ltd.
» End-Use (Specialty Clinics, Hospitals, Pharmacies) » Route of Administration (Parenteral, Inhalation, Oral) » Treatment (Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy, Other Treatments)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Global Competitor Market Shares |
| Alpha 1 Antitrypsin Deficiency Treatment Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| Alpha 1 Antitrypsin Deficiency Treatment Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017 |
| Alpha 1 Antitrypsin Deficiency Treatment Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 |
| Augmentation Therapy (Treatment) World Market by Region/Country in US$ Thousand: 2018 to 2025 |
| Augmentation Therapy (Treatment) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 |
| Augmentation Therapy (Treatment) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 |
| Bronchodilator (Treatment) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025 |
| Bronchodilator (Treatment) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017 |
| Bronchodilator (Treatment) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 |
| Corticosteroids (Treatment) Geographic Market Spread Worldwide in US$ Thousand: 2018 to 2025 |
| Corticosteroids (Treatment) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2009 to 2017 |
| Corticosteroids (Treatment) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Oxygen Therapy (Treatment) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2018 to 2025 |
| Oxygen Therapy (Treatment) Market Historic Review by Region/Country in US$ Thousand: 2009 to 2017 |
| Oxygen Therapy (Treatment) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 |
| Other Treatments (Treatment) World Market by Region/Country in US$ Thousand: 2018 to 2025 |
| Other Treatments (Treatment) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 |
| Other Treatments (Treatment) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Parenteral (Route of Administration) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025 |
| Parenteral (Route of Administration) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017 |
| Parenteral (Route of Administration) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 |
| Inhalation (Route of Administration) Geographic Market Spread Worldwide in US$ Thousand: 2018 to 2025 |
| Inhalation (Route of Administration) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2009 to 2017 |
| Inhalation (Route of Administration) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Oral (Route of Administration) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2018 to 2025 |
| Oral (Route of Administration) Market Historic Review by Region/Country in US$ Thousand: 2009 to 2017 |
| Oral (Route of Administration) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 |
| Specialty Clinics (End-Use) Sales Estimates and Forecasts in US$ Thousand by Region/Country for the Years 2018 through 2025 |
| Specialty Clinics (End-Use) Analysis of Historic Sales in US$ Thousand by Region/Country for the Years 2009 to 2017 |
| Specialty Clinics (End-Use) Global Market Share Distribution by Region/Country for 2009, 2019, and 2025 |
| Hospitals (End-Use) Global Opportunity Assessment in US$ Thousand by Region/Country: 2018-2025 |
| Hospitals (End-Use) Historic Sales Analysis in US$ Thousand by Region/Country: 2009-2017 |
| Hospitals (End-Use) Percentage Share Breakdown of Global Sales by Region/Country: 2009 VS 2019 VS 2025 |
| Pharmacies (End-Use) Worldwide Sales in US$ Thousand by Region/Country: 2018-2025 |
| Pharmacies (End-Use) Historic Demand Patterns in US$ Thousand by Region/Country: 2009-2017 |
| Pharmacies (End-Use) Market Share Shift across Key Geographies: 2009 VS 2019 VS 2025 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| UNITED STATES |
| Market Facts & Figures |
| US Alpha 1 Antitrypsin Deficiency Treatment Market Share (in %) by Company: 2019 & 2025 |
| United States Alpha 1 Antitrypsin Deficiency Treatment Market Estimates and Projections in US$ Thousand by Treatment: 2018 to 2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in the United States by Treatment: A Historic Review in US$ Thousand for 2009-2017 |
| United States Alpha 1 Antitrypsin Deficiency Treatment Market Share Breakdown by Treatment: 2009 VS 2019 VS 2025 |
| United States Alpha 1 Antitrypsin Deficiency Treatment Market Estimates and Projections in US$ Thousand by Route of Administration: 2018 to 2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in the United States by Route of Administration: A Historic Review in US$ Thousand for 2009-2017 |
| United States Alpha 1 Antitrypsin Deficiency Treatment Market Share Breakdown by Route of Administration: 2009 VS 2019 VS 2025 |
| United States Alpha 1 Antitrypsin Deficiency Treatment Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Historic Demand Patterns in the United States by End-Use in US$ Thousand for 2009-2017 |
| Alpha 1 Antitrypsin Deficiency Treatment Market Share Breakdown in the United States by End-Use: 2009 VS 2019 VS 2025 |
| CANADA |
| Canadian Alpha 1 Antitrypsin Deficiency Treatment Market Estimates and Forecasts in US$ Thousand by Treatment: 2018 to 2025 |
| Canadian Alpha 1 Antitrypsin Deficiency Treatment Historic Market Review by Treatment in US$ Thousand: 2009-2017 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Canada: Percentage Share Breakdown of Sales by Treatment for 2009, 2019, and 2025 |
| Canadian Alpha 1 Antitrypsin Deficiency Treatment Market Estimates and Forecasts in US$ Thousand by Route of Administration: 2018 to 2025 |
| Canadian Alpha 1 Antitrypsin Deficiency Treatment Historic Market Review by Route of Administration in US$ Thousand: 2009-2017 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Canada: Percentage Share Breakdown of Sales by Route of Administration for 2009, 2019, and 2025 |
| Canadian Alpha 1 Antitrypsin Deficiency Treatment Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2018 to 2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 |
| Canadian Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 |
| JAPAN |
| Japanese Market for Alpha 1 Antitrypsin Deficiency Treatment: Annual Sales Estimates and Projections in US$ Thousand by Treatment for the Period 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Japan: Historic Sales Analysis in US$ Thousand by Treatment for the Period 2009-2017 |
| Japanese Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis by Treatment: 2009 VS 2019 VS 2025 |
| Japanese Market for Alpha 1 Antitrypsin Deficiency Treatment: Annual Sales Estimates and Projections in US$ Thousand by Route of Administration for the Period 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Japan: Historic Sales Analysis in US$ Thousand by Route of Administration for the Period 2009-2017 |
| Japanese Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis by Route of Administration: 2009 VS 2019 VS 2025 |
| Japanese Demand Estimates and Forecasts for Alpha 1 Antitrypsin Deficiency Treatment in US$ Thousand by End-Use: 2018 to 2025 |
| Japanese Alpha 1 Antitrypsin Deficiency Treatment Market in US$ Thousand by End-Use: 2009-2017 |
| Alpha 1 Antitrypsin Deficiency Treatment Market Share Shift in Japan by End-Use: 2009 VS 2019 VS 2025 |
| CHINA |
| Chinese Alpha 1 Antitrypsin Deficiency Treatment Market Growth Prospects in US$ Thousand by Treatment for the Period 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Historic Market Analysis in China in US$ Thousand by Treatment: 2009-2017 |
| Chinese Alpha 1 Antitrypsin Deficiency Treatment Market by Treatment: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Chinese Alpha 1 Antitrypsin Deficiency Treatment Market Growth Prospects in US$ Thousand by Route of Administration for the Period 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Historic Market Analysis in China in US$ Thousand by Route of Administration: 2009-2017 |
| Chinese Alpha 1 Antitrypsin Deficiency Treatment Market by Route of Administration: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Chinese Demand for Alpha 1 Antitrypsin Deficiency Treatment in US$ Thousand by End-Use: 2018 to 2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market Review in China in US$ Thousand by End-Use: 2009-2017 |
| Chinese Alpha 1 Antitrypsin Deficiency Treatment Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 |
| EUROPE |
| Market Facts & Figures |
| European Alpha 1 Antitrypsin Deficiency Treatment Market: Competitor Market Share Scenario (in %) for 2019 & 2025 |
| European Alpha 1 Antitrypsin Deficiency Treatment Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017 |
| European Alpha 1 Antitrypsin Deficiency Treatment Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 |
| European Alpha 1 Antitrypsin Deficiency Treatment Market Estimates and Forecasts in US$ Thousand by Treatment: 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Europe in US$ Thousand by Treatment: A Historic Review for the Period 2009-2017 |
| European Alpha 1 Antitrypsin Deficiency Treatment Market Share Breakdown by Treatment: 2009 VS 2019 VS 2025 |
| European Alpha 1 Antitrypsin Deficiency Treatment Market Estimates and Forecasts in US$ Thousand by Route of Administration: 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Europe in US$ Thousand by Route of Administration: A Historic Review for the Period 2009-2017 |
| European Alpha 1 Antitrypsin Deficiency Treatment Market Share Breakdown by Route of Administration: 2009 VS 2019 VS 2025 |
| European Alpha 1 Antitrypsin Deficiency Treatment Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 |
| European Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 |
| FRANCE |
| Alpha 1 Antitrypsin Deficiency Treatment Market in France by Treatment: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| French Alpha 1 Antitrypsin Deficiency Treatment Historic Market Scenario in US$ Thousand by Treatment: 2009-2017 |
| French Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis by Treatment: 2009 VS 2019 VS 2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in France by Route of Administration: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| French Alpha 1 Antitrypsin Deficiency Treatment Historic Market Scenario in US$ Thousand by Route of Administration: 2009-2017 |
| French Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis by Route of Administration: 2009 VS 2019 VS 2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Quantitative Demand Analysis in France in US$ Thousand by End-Use: 2018-2025 |
| French Alpha 1 Antitrypsin Deficiency Treatment Historic Market Review in US$ Thousand by End-Use: 2009-2017 |
| French Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 |
| GERMANY |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Treatment for the Period 2018-2025 |
| German Alpha 1 Antitrypsin Deficiency Treatment Historic Market Analysis in US$ Thousand by Treatment: 2009-2017 |
| German Alpha 1 Antitrypsin Deficiency Treatment Market Share Breakdown by Treatment: 2009 VS 2019 VS 2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Route of Administration for the Period 2018-2025 |
| German Alpha 1 Antitrypsin Deficiency Treatment Historic Market Analysis in US$ Thousand by Route of Administration: 2009-2017 |
| German Alpha 1 Antitrypsin Deficiency Treatment Market Share Breakdown by Route of Administration: 2009 VS 2019 VS 2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 |
| German Alpha 1 Antitrypsin Deficiency Treatment Market in Retrospect in US$ Thousand by End-Use: 2009-2017 |
| Alpha 1 Antitrypsin Deficiency Treatment Market Share Distribution in Germany by End-Use: 2009 VS 2019 VS 2025 |
| ITALY |
| Italian Alpha 1 Antitrypsin Deficiency Treatment Market Growth Prospects in US$ Thousand by Treatment for the Period 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Historic Market Analysis in Italy in US$ Thousand by Treatment: 2009-2017 |
| Italian Alpha 1 Antitrypsin Deficiency Treatment Market by Treatment: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Italian Alpha 1 Antitrypsin Deficiency Treatment Market Growth Prospects in US$ Thousand by Route of Administration for the Period 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Historic Market Analysis in Italy in US$ Thousand by Route of Administration: 2009-2017 |
| Italian Alpha 1 Antitrypsin Deficiency Treatment Market by Route of Administration: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Italian Demand for Alpha 1 Antitrypsin Deficiency Treatment in US$ Thousand by End-Use: 2018 to 2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market Review in Italy in US$ Thousand by End-Use: 2009-2017 |
| Italian Alpha 1 Antitrypsin Deficiency Treatment Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 |
| UNITED KINGDOM |
| United Kingdom Market for Alpha 1 Antitrypsin Deficiency Treatment: Annual Sales Estimates and Projections in US$ Thousand by Treatment for the Period 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Treatment for the Period 2009-2017 |
| United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis by Treatment: 2009 VS 2019 VS 2025 |
| United Kingdom Market for Alpha 1 Antitrypsin Deficiency Treatment: Annual Sales Estimates and Projections in US$ Thousand by Route of Administration for the Period 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Route of Administration for the Period 2009-2017 |
| United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis by Route of Administration: 2009 VS 2019 VS 2025 |
| United Kingdom Demand Estimates and Forecasts for Alpha 1 Antitrypsin Deficiency Treatment in US$ Thousand by End-Use: 2018 to 2025 |
| United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market in US$ Thousand by End-Use: 2009-2017 |
| Alpha 1 Antitrypsin Deficiency Treatment Market Share Shift in the United Kingdom by End-Use: 2009 VS 2019 VS 2025 |
| REST OF EUROPE |
| Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Market Estimates and Forecasts in US$ Thousand by Treatment: 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Rest of Europe in US$ Thousand by Treatment: A Historic Review for the Period 2009-2017 |
| Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share Breakdown by Treatment: 2009 VS 2019 VS 2025 |
| Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Market Estimates and Forecasts in US$ Thousand by Route of Administration: 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Rest of Europe in US$ Thousand by Route of Administration: A Historic Review for the Period 2009-2017 |
| Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share Breakdown by Route of Administration: 2009 VS 2019 VS 2025 |
| Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Rest of Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 |
| Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 |
| ASIA-PACIFIC |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Asia-Pacific by Treatment: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Historic Market Scenario in US$ Thousand by Treatment: 2009-2017 |
| Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis by Treatment: 2009 VS 2019 VS 2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Asia-Pacific by Route of Administration: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Historic Market Scenario in US$ Thousand by Route of Administration: 2009-2017 |
| Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis by Route of Administration: 2009 VS 2019 VS 2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by End-Use: 2018-2025 |
| Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Historic Market Review in US$ Thousand by End-Use: 2009-2017 |
| Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 |
| REST OF WORLD |
| Rest of World Alpha 1 Antitrypsin Deficiency Treatment Market Estimates and Forecasts in US$ Thousand by Treatment: 2018 to 2025 |
| Rest of World Alpha 1 Antitrypsin Deficiency Treatment Historic Market Review by Treatment in US$ Thousand: 2009-2017 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Rest of World: Percentage Share Breakdown of Sales by Treatment for 2009, 2019, and 2025 |
| Rest of World Alpha 1 Antitrypsin Deficiency Treatment Market Estimates and Forecasts in US$ Thousand by Route of Administration: 2018 to 2025 |
| Rest of World Alpha 1 Antitrypsin Deficiency Treatment Historic Market Review by Route of Administration in US$ Thousand: 2009-2017 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Rest of World: Percentage Share Breakdown of Sales by Route of Administration for 2009, 2019, and 2025 |
| Rest of World Alpha 1 Antitrypsin Deficiency Treatment Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2018 to 2025 |
| Alpha 1 Antitrypsin Deficiency Treatment Market in Rest of World: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 |
| Rest of World Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 |
| IV. COMPETITION |
| Total Companies Profiled : 17 Click here to request a full table of contents and more details on this project. |
| V. CURATED RESEARCH |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com